Molecular mechanisms of immunogenic cell death and tumor-specific immune activation via unfolded protein response (UPR) activation by anticancer drugs
Molecular mechanisms of immunogenic cell death and tumor-specific immune activation via unfolded protein response (UPR) activation by anticancer drugs. When anticancer drugs are administered, cancer cells exceed the UPR threshold to the point of lethality, activating the double-stranded RNA-activated protein kinase-like ER kinase (PERK) and inositol-requiring 1 (IRE1) signaling pathways and activating transcription factor 4 (ATF4) and growth arrest- and DNA damage-inducible gene 153 (Gadd153)/CCAAT/enhancer-binding protein homologous protein (CHOP) induction, which in turn downregulates X-linked inhibitor of apoptotic protein (XIAP), decreasing antiapoptotic and increasing proapoptotic B-cell lymphoma 2 (Bcl-2) protein expression, leading to cell death. In this process, dying cancer cells externalize calreticulin (CRT) to the membrane surface and release damage-associated molecular patterns (DAMPs) such as ATP, annexin 1, and high mobility group box 1 (HMGB1) for immune activation. Dendritic cells (DCs) are recruited and activated by the secretion of ATP that binds to P2RY2 and P2RX7 receptors. They are then homed by the binding of released annexin 1 to formyl peptide receptor 1 (FPR1). CRT stimulates the phagocytosis of dying cancer cells by binding to CD91 receptors on DCs. HMGB1 release stimulates DC recruitment via binding to receptor for advanced glycation end products (RAGE) receptors and induces DC maturation via toll-like receptor 4 (TLR4) signaling. Mature DCs migrate to lymph nodes, where they cross-prime and cause the clonal expansion of T cells, including interleukin 12 (IL-12) and type I interferon (IFN). IFN-γ-producing T cells are recruited and exert cytotoxic responses to eradicate cancer cells. Tumor antigens (TAs) released from dying cells are taken up by immature DCs, which then activate and mature. TAs and tumor-associated antigens (TAAs) are processed in mature DCs and presented to CD8+ T cells as major histocompatibility complex I (MHC I) molecules, generating cytotoxic T lymphocytes (CTLs) for tumor-specific immune responses. This figure was custom-made by Wiley Editing Services based on our freehand drawing